Taysha GTx
Taysha Gene Therapies is a clinical-stage biotechnology company focused on developing AAV-based gene therapies for severe monogenic diseases of the central nervous system. Its lead program TSHA-102 targets Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies. Founded in 2020 and headquartered in Dallas, Texas, the company's management team has proven experience in gene therapy development and commercialization.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountSep 2020
Aug 2020
Apr 2020
Create a free account to see which investors have funded this company.
Create Free Account
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Health insurance company using technology to make health care simple, affordable, and accessible.
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
